WALTHAM, Mass. and KING OF PRUSSIA, Penn., May 27, 2020 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE:TMO), the world leader in serving science,
and global biotechnology company, CSL Limited (ASX:CSL;USOTC:CSLLY)
today announced they have entered into a strategic partnership to
help meet the growing demand for biologic therapies while also
accelerating CSL's broader manufacturing objectives.
Thermo Fisher will support CSL's
product portfolio by leveraging its pharma services network,
including drug product development, biologics manufacturing,
sterile fill-finish, packaging and clinical trials logistics.
Through a long-term lease agreement with CSL, Thermo Fisher will operate a new
state-of-the-art biologics manufacturing facility in Lengnau,
Switzerland, when construction is
completed in mid-2021.
"We continue to invest to meet the growing need for flexible
biologics capacity, and Lengnau will significantly expand our
pharma services capacity and capabilities," said Michel Lagarde, executive vice president of
Thermo Fisher Scientific. "This partnership clearly strengthens our
unique customer value proposition, which leverages our scale and
depth of capabilities for pharma and biotech customers. In addition
to adding a high-volume production site, we can also address a
broadening range of manufacturing needs for our customers,
including CSL. This approach creates a win/win by making it simple
for customers to start with us and stay with us as their
requirements grow."
Within the Lengnau site, Thermo
Fisher will support manufacturing of CSL's next-generation
product for hemophilia patients. The site will feature highly
flexible bioproduction technologies, including single-use and
stainless steel, to provide a pathway from development to
large-scale production as customers' needs increase. Over time,
Thermo Fisher plans to expand the
use of the site to include additional biopharma customers.
Paul McKenzie, chief operating
officer, CSL, said, "As part of the CSL Board of Directors'
strategic review, we are in the process of transforming our
end-to-end supply chain with a view to ensuring the company's
global manufacturing network is operating at a best-in-class level.
This includes balancing internal investment with access to
capabilities and capacities that are available with an experienced
partner. Through this strategic partnership with Thermo Fisher, CSL will now be able to access a
wide range of capabilities provided by a leading pharma services
provider, and we are confident that the management of the Lengnau
facility and team will be in the very best of
hands."
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving
science, with annual revenue exceeding $25
billion. Our Mission is to enable our customers to make the
world healthier, cleaner and safer. Whether our customers are
accelerating life sciences research, solving complex analytical
challenges, improving patient diagnostics and therapies or
increasing productivity in their laboratories, we are here to
support them. Our global team of more than 75,000 colleagues
delivers an unrivaled combination of innovative technologies,
purchasing convenience and pharmaceutical services through our
industry-leading brands, including Thermo Scientific, Applied
Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and
Patheon. For more information, please visit
www.thermofisher.com.
About CSL
CSL (ASX:CSL) is a leading global biotechnology company with a
dynamic portfolio of life-saving medicines, including those that
treat hemophilia and immune deficiencies, as well as vaccines to
prevent seasonal and pandemic influenza. Since our start in 1916,
we have been driven by our promise to save lives using the latest
technologies. Today, CSL – including our two businesses, CSL
Behring and Seqirus - provides life-saving products to more than 70
countries and employs more than 26,000 people. Our unique
combination of commercial strength, R&D focus and operational
excellence enables us to identify, develop and deliver innovations
so our patients and communities can live life to the fullest. For
more information about CSL Limited, visit
www.csl.com.
Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Website: www.thermofisher.com
Investor Contact Information:
Ken Apicerno
Phone: 781-622-1294
E-mail: ken.apicerno@thermofisher.com
Natalie de Vane
CSL Limited
Phone: 610-999-8756
E-mail: natalie.devane@cslbehring.com
Mark Dehring
CSL Limited
Phone: +61 393 893 407
Email: mark.dehring@csl.com.au
View original content to download
multimedia:http://www.prnewswire.com/news-releases/thermo-fisher-scientific-and-csl-enter-strategic-partnership-to-provide-best-in-class-pharma-services-301065659.html
SOURCE Thermo Fisher Scientific